Nuvalent, Inc.(NUVL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NUVL Nuvalent, Inc.

盘前交易 06-03 06:03:38 EDT

91.35

-1.66

-1.78%

盘前91.60

+0.25+0.27%

05:26 EDT

最高94.12	最低89.20	成交量172.32万
今开93.31	昨收93.01	日振幅5.30%
总市值72.15亿	流通市值52.93亿	总股本7,898万
成交额1.57亿	换手率2.97%	流通股本5,794万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NUVL","market":"US","secType":"STK","nameCN":"Nuvalent, Inc.","latestPrice":91.35,"timestamp":1780430400000,"preClose":93.01,"halted":0,"volume":1723225,"hourTrading":{"tag":"盘前","latestPrice":91.6,"preClose":91.35,"latestTime":"05:26 EDT","volume":210,"amount":19189.4997,"timestamp":1780478800376,"change":0.25,"changeRate":0.002737,"amplitude":0.005911},"delay":0,"changeRate":-0.01784754327491679,"floatShares":57942920,"shares":78978000,"eps":-6.06,"marketStatus":"盘前交易","change":-1.66,"latestTime":"06-03 06:03:38 EDT","open":93.31,"high":94.12,"low":89.195,"amount":156841839.2835,"amplitude":0.052951,"askPrice":96.62,"askSize":100,"bidPrice":86.05,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-6.06,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780493400000},"marketStatusCode":1,"adr":0,"listingDate":1627531200000,"exchange":"NASDAQ","adjPreClose":91.35,"preHourTrading":{"tag":"盘前","latestPrice":91.6,"preClose":91.35,"latestTime":"05:26 EDT","volume":210,"amount":19189.4997,"timestamp":1780478800376,"change":0.25,"changeRate":0.002737,"amplitude":0.005911},"postHourTrading":{"tag":"盘后","latestPrice":91,"preClose":91.35,"latestTime":"19:31 EDT","volume":29408,"amount":2711668.71,"timestamp":1780443091308,"change":-0.35,"changeRate":-0.003831,"amplitude":0.033935},"volumeRatio":1.4616055068921876,"impliedVol":0.5019,"impliedVolPercentile":0.748},"requestUrl":"/m/hq/s/NUVL","defaultTab":"news","newsList":[{"id":"1172180016","title":"Nuvalent公布关键项目与业务进展，巩固其在ROS1与ALK阳性非小细胞肺癌领域的全球领导地位基础","url":"https://stock-news.laohu8.com/highlight/detail?id=1172180016","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172180016?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:30","pubTimestamp":1779877820,"startTime":"0","endTime":"0","summary":"Nuvalent公司宣布了其关键研发项目与业务运营的重要更新，此举进一步夯实了该公司在针对ROS1与ALK阳性非小细胞肺癌治疗领域，实现全球领导地位的战略根基。这些进展涵盖了从管线推进到企业运营的多个层面，彰显了公司致力于为患者带来变革性疗法的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138597174","title":"Nuvalent公司：现有资金、现金等价物及有价证券足以支撑其运营至2029年","url":"https://stock-news.laohu8.com/highlight/detail?id=1138597174","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138597174?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:40","pubTimestamp":1778150425,"startTime":"0","endTime":"0","summary":"生物制药公司Nuvalent, Inc.宣布，其现有的现金储备、现金等价物以及可流通有价证券，预计将能够为公司的持续运营和研发活动提供充足的资金支持，直至2029年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164810657","title":"Nuvalent公布近期管线进展，重申关键预期里程碑及2026年第一季度财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1164810657","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164810657?lang=zh_cn&edition=full","pubTime":"2026-05-07 18:34","pubTimestamp":1778150073,"startTime":"0","endTime":"0","summary":"Nuvalent公司近日重点介绍了其研发管线的最新进展，再次明确了未来关键的预期里程碑节点，并同步发布了2026年第一季度的财务报告。\n公司管理层在更新中强调了其在研项目取得的实质性推进，同时重申了对即将到来的重要发展时间点的预期。此外，2026年首季的财务业绩数据也一并公布，为投资者提供了全面的运营和财务视角。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144205337","title":"Nuvalent向FDA提交新药申请，寻求批准Neladalkib用于TKI经治的ALK阳性晚期非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1144205337","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144205337?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:33","pubTimestamp":1775557994,"startTime":"0","endTime":"0","summary":"生物制药公司Nuvalent, Inc.宣布，已正式向美国食品药品监督管理局（FDA）提交了其研究性药物Neladalkib的新药申请（NDA）。该申请旨在寻求批准Neladalkib用于治疗既往接受过酪氨酸激酶抑制剂（TKI）治疗的间变性淋巴瘤激酶（ALK）阳性晚期非小细胞肺癌（NSCLC）患者。\n这一重要监管里程碑标志着该药物在开发进程中迈出了关键一步，若获批准，将为这类患者群体提供一个新的潜在治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","NUVL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160862794","title":"Nuvalent公布近期研发管线进展，重申关键预期里程碑，并报告2025年第四季度及全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1160862794","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160862794?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:32","pubTimestamp":1772105558,"startTime":"0","endTime":"0","summary":"Nuvalent, Inc. (纳斯达克代码: NUVL) 近日披露了其研发管线的最新动态，再次强调了未来重要的预期里程碑节点，同时公布了公司2025财年第四季度及全年的财务业绩报告。\n公司管理层详细介绍了其在研项目取得的实质性进展，特别是在靶向疗法领域。这些进展进一步巩固了其在精准肿瘤学药物开发方面的领先地位。与此同时，财务数据显示了公司在战略投资研发与维持财务健康之间取得的平衡。\n此次信息更新为投资者和行业观察人士提供了评估公司未来发展轨迹和潜在价值的关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","NUVL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600308304","title":"Nuvalent, Inc.跌0.40% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2600308304","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600308304?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:31","pubTimestamp":1767191464,"startTime":"0","endTime":"0","summary":"北京时间2025年12月31日22时31分，Nuvalent, Inc.股票出现波动，股价快速跳水0.40%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Vanda Pharmaceuticals Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 涨幅较大，Fibrobiologics, Inc.、Gri Bio, Inc.、Pmgc Holdings Inc.较为活跃，换手率分别为22.66%、14.08%、14.01%，振幅较大的相关个股有Gri Bio, Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Outlook Therapeutics, Inc.，振幅分别为7.66%、7.41%、5.90%。Nuvalent, Inc.公司简介：Nuvalent Inc 是一家临床阶段生物制药公司，专注于为癌症患者研发精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231223105a6e5f6fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251231223105a6e5f6fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518202206","title":"Nuvalent, Inc.盘中异动 急速下挫5.08%报67.46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518202206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518202206?lang=zh_cn&edition=full","pubTime":"2025-03-11 03:13","pubTimestamp":1741634026,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日03时13分，Nuvalent, Inc.股票出现波动，股价急速下跌5.08%。截至发稿，该股报67.46美元/股，成交量71.6696万股，换手率1.00%，振幅3.74%。Nuvalent, Inc.股票所在的生物技术行业中，整体涨幅为0.32%。Nuvalent, Inc.公司简介：Nuvalent Inc是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311031346a26aa563&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311031346a26aa563&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517162594","title":"Nuvalent, Inc.2024财年实现净利润-2.61亿美元，同比减少107.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517162594","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517162594?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:01","pubTimestamp":1741276864,"startTime":"0","endTime":"0","summary":"3月7日，Nuvalent, Inc.公布财报，公告显示公司2024财年净利润为-2.61亿美元，同比减少107.14%；其中营业收入为0.00美元，每股基本收益为-3.93美元。从资产负债表来看，Nuvalent, Inc.总负债71.96百万美元，其中短期债务0.00美元，资产负债比为0.16，流动比率为0.21。机构评级：截至2025年3月7日，当前有11家机构对Nuvalent, Inc.目标价做出预测，其中目标均价为113.73美元，其中最低目标价为100.00美元，最高目标价为137.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000122abeb8d0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000122abeb8d0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194057199","title":"Nuvalent 2024年第四季度每股亏损1.05美元，超出分析师预期的1.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194057199","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194057199?lang=zh_cn&edition=full","pubTime":"2025-02-27 19:40","pubTimestamp":1740656431,"startTime":"0","endTime":"0","summary":"Nuvalent报告其每股季度亏损1.05美元，超出分析师普遍预期的1.08美元，比预期高出2.78%。与去年同期的每股亏损0.62美元相比，亏损增加了69.35%。以上内容来自Benzinga Earnings专栏，原文如下：Nuvalent  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 2.78 percent. This is a 69.35 percent decrease over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nuvalent 2024年第四季度每股亏损1.05美元，超出分析师预期的1.08美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509231289","title":"Nuvalent, Inc.盘中异动 快速拉升5.21%报90.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509231289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509231289?lang=zh_cn&edition=full","pubTime":"2025-02-06 00:51","pubTimestamp":1738774271,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日00时51分，Nuvalent, Inc.股票出现异动，股价快速拉升5.21%。截至发稿，该股报90.40美元/股，成交量11.0499万股，换手率0.16%，振幅5.74%。Nuvalent, Inc.股票所在的生物技术行业中，整体涨幅为1.86%。Nuvalent, Inc.公司简介：Nuvalent Inc是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206005111a23a9a34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206005111a23a9a34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NUVL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503625354","title":"Nuvalent, Inc.盘中异动 快速上涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503625354","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503625354?lang=zh_cn&edition=full","pubTime":"2025-01-15 23:22","pubTimestamp":1736954562,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日23时22分，Nuvalent, Inc.股票出现波动，股价急速上涨5.01%。Nuvalent, Inc.股票所在的生物技术行业中，整体涨幅为1.35%。其相关个股中，Klotho Neurosciences Inc C/Wts 21/06/2029 、Lexaria Bioscience Corp C/Wts 14/01/2026 、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Windtree Therapeutics, Inc.、Phio Pharmaceuticals Corp.、Os Therapies Incorporated较为活跃，换手率分别为204.99%、140.13%、77.83%，振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Os Therapies Incorporated、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 ，振幅分别为68.03%、61.30%、54.40%。Nuvalent, Inc.公司简介：Nuvalent Inc是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152322429604c276&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152322429604c276&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503589256","title":"Nuvalent, Inc.盘中异动 早盘快速下跌5.20%报72.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503589256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503589256?lang=zh_cn&edition=full","pubTime":"2025-01-13 23:12","pubTimestamp":1736781160,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日23时12分，Nuvalent, Inc.股票出现波动，股价急速下跌5.20%。截至发稿，该股报72.63美元/股，成交量2.7987万股，换手率0.04%，振幅4.60%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为1.13%。Nuvalent, Inc.公司简介：Nuvalent Inc是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011323124196025b6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011323124196025b6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2492159090","title":"Nuvalent, Inc.盘中异动 临近收盘股价大跌5.12%报83.59美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492159090","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492159090?lang=zh_cn&edition=full","pubTime":"2024-12-19 04:40","pubTimestamp":1734554406,"startTime":"0","endTime":"0","summary":"北京时间2024年12月19日04时40分，Nuvalent, Inc.股票出现异动，股价急速下挫5.12%。截至发稿，该股报83.59美元/股，成交量18.4705万股，换手率0.26%，振幅4.67%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为2.83%。Nuvalent, Inc.公司简介：Nuvalent Inc是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121904400795ea5ae9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121904400795ea5ae9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NUVL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2490077381","title":"Nuvalent, Inc.盘中异动 早盘股价大跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490077381","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490077381?lang=zh_cn&edition=full","pubTime":"2024-12-12 22:32","pubTimestamp":1734013934,"startTime":"0","endTime":"0","summary":"北京时间2024年12月12日22时32分，Nuvalent, Inc.股票出现波动，股价大幅跳水5.12%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为0.37%。其相关个股中，Palisade Bio, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Trevi Therapeutics, Inc.涨幅较大，Palisade Bio, Inc.、Aptevo Therapeutics Inc.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为1909.98%、448.84%、50.59%，振幅较大的相关个股有Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Aptevo Therapeutics Inc.、Palisade Bio, Inc.，振幅分别为54.53%、17.38%、17.14%。Nuvalent, Inc.公司简介：Nuvalent Inc是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212223214ab72a87a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212223214ab72a87a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2484691559","title":"Nuvalent, Inc.2024财年第三财季实现净利润-84.35百万美元，同比减少150.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484691559","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484691559?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010412,"startTime":"0","endTime":"0","summary":"11月19日，Nuvalent, Inc.公布财报，公告显示公司2024财年第三财季净利润为-84.35百万美元，同比减少150.67%；其中营业收入为0.00美元，每股基本收益为-1.28美元。从资产负债表来看，Nuvalent, Inc.总负债67.73百万美元，其中短期债务0.00美元，资产负债比为0.18，流动比率为0.24。机构评级：截至2024年11月19日，当前有12家机构对Nuvalent, Inc.目标价做出预测，其中目标均价为115.83美元，其中最低目标价为100.00美元，最高目标价为137.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180020a245619e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180020a245619e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2477042538","title":"Nuvalent, Inc.跌5.08% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2477042538","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477042538?lang=zh_cn&edition=full","pubTime":"2024-10-23 21:31","pubTimestamp":1729690271,"startTime":"0","endTime":"0","summary":"北京时间2024年10月23日21时31分，Nuvalent, Inc.股票出现异动，股价大幅下跌5.08%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为0.17%。其相关个股中，Cns Pharmaceuticals, Inc.、Virax Biolabs Group Limited、Dbv Technologies涨幅较大，Virax Biolabs Group Limited、Cns Pharmaceuticals, Inc.、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为842.55%、474.19%、266.63%，振幅较大的相关个股有Cns Pharmaceuticals, Inc.、Virax Biolabs Group Limited、Okyo Pharma Ltd Com Npv ，振幅分别为27.06%、17.26%、13.56%。Nuvalent, Inc.公司简介：Nuvalent Inc是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102321311195bd428c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102321311195bd428c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2474443547","title":"Nuvalent, Inc.跌1.46% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2474443547","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474443547?lang=zh_cn&edition=full","pubTime":"2024-10-10 21:57","pubTimestamp":1728568675,"startTime":"0","endTime":"0","summary":"北京时间2024年10月10日21时57分，Nuvalent, Inc.股票出现异动，股价快速下挫1.46%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为0.42%。其相关个股中，Tc Biopharm  Plc C/Wts 10/02/2028 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Aditxt, Inc.、Tempest Therapeutics, Inc.、Clearmind Medicine Inc.较为活跃，换手率分别为210.06%、128.20%、104.09%，振幅较大的相关个股有Genenta Science Spa、Tevogen Bio Holdings Inc.、Gri Bio, Inc.，振幅分别为25.48%、20.40%、18.60%。Nuvalent, Inc.公司简介：Nuvalent Inc是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101021575598e3bbbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101021575598e3bbbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","NUVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2472937770","title":"Nuvalent, Inc.跌2.25% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2472937770","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472937770?lang=zh_cn&edition=full","pubTime":"2024-10-01 23:02","pubTimestamp":1727794969,"startTime":"0","endTime":"0","summary":"北京时间2024年10月01日23时02分，Nuvalent, Inc.股票出现异动，股价快速下跌2.25%。截至发稿，该股报100.00美元/股，成交量17.1446万股，换手率0.24%，振幅2.14%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为0.38%。Nuvalent, Inc.公司简介：Nuvalent Inc是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410012302499719db98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410012302499719db98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2471857953","title":"Nuvalent, Inc.涨1.58% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2471857953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471857953?lang=zh_cn&edition=full","pubTime":"2024-09-30 21:48","pubTimestamp":1727704136,"startTime":"0","endTime":"0","summary":"北京时间2024年09月30日21时48分，Nuvalent, Inc.股票出现异动，股价快速上涨1.58%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Prime Medicine, Inc.、Kezar Life Sciences, Inc.、Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024 涨幅较大，Aditxt, Inc.、Onconetix, Inc.、Seelos Therapeutics, Inc.较为活跃，换手率分别为56.35%、22.99%、22.59%，振幅较大的相关个股有Coeptis Therapeutics Holdings Inc C/Wts 31/12/2024 、Cingulate Inc C/Wts 10/12/2026 、Plus Therapeutics, Inc.，振幅分别为32.54%、31.55%、28.10%。Nuvalent, Inc.公司简介：Nuvalent Inc是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409302148569719d9a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409302148569719d9a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2470805378","title":"Nuvalent, Inc.跌1.27% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2470805378","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470805378?lang=zh_cn&edition=full","pubTime":"2024-09-28 03:04","pubTimestamp":1727463885,"startTime":"0","endTime":"0","summary":"北京时间2024年09月28日03时04分，Nuvalent, Inc.股票出现波动，股价大幅下跌1.27%。Nuvalent, Inc.股票所在的生物技术行业中，整体跌幅为0.96%。其相关个股中，Nls Pharmaceutics Ltd C/Wts 02/02/2026、Onconetix, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Onconetix, Inc.、Seelos Therapeutics, Inc.、Aditxt, Inc.较为活跃，换手率分别为4459.67%、277.36%、151.98%，振幅较大的相关个股有Pasithea Therapeutics Corp C/Wts 12/08/2026 、Estrella Immunopharma Inc C/Wts 29/09/2028、Estrella Immunopharma, Inc.，振幅分别为167.75%、69.81%、65.94%。Nuvalent, Inc.公司简介：Nuvalent Inc是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092803044598e39761&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092803044598e39761&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVL","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nuvalent.com","stockEarnings":[{"period":"1week","weight":-0.1296},{"period":"1month","weight":-0.0776},{"period":"3month","weight":-0.1103},{"period":"6month","weight":-0.1451},{"period":"1year","weight":0.1836},{"period":"ytd","weight":-0.0919}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.054},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.1098},{"period":"1year","weight":0.2815},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nuvalent, Inc.于2017年1月25日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于为癌症患者创造精准靶向疗法。该公司利用团队在化学和基于结构的药物设计方面的深厚专业知识，开发创新的小分子，其设计旨在克服现有疗法对临床证明的激酶靶点的限制。目前可用的激酶抑制剂面临的限制可能包括（i）激酶耐药性，或激酶靶点出现新的突变，从而能够对现有疗法产生耐药性，（ii）激酶选择性，或现有疗法可能抑制结构相似的激酶靶点并导致脱靶不良事件，以及（iii）有限的脑外显率，或该疗法治疗已经扩散或转移到大脑的疾病的能力。","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":-0.027036},{"month":2,"riseRate":0.6,"avgChangeRate":0.018654},{"month":3,"riseRate":0.2,"avgChangeRate":-0.073231},{"month":4,"riseRate":0.4,"avgChangeRate":0.01512},{"month":5,"riseRate":0.4,"avgChangeRate":0.015248},{"month":6,"riseRate":0.8,"avgChangeRate":0.107672},{"month":7,"riseRate":1,"avgChangeRate":0.08966},{"month":8,"riseRate":0.6,"avgChangeRate":0.217715},{"month":9,"riseRate":0.8,"avgChangeRate":0.02208},{"month":10,"riseRate":0.8,"avgChangeRate":0.213383},{"month":11,"riseRate":0.6,"avgChangeRate":0.048468},{"month":12,"riseRate":0.2,"avgChangeRate":-0.069265}],"exchange":"NASDAQ","name":"Nuvalent, Inc.","nameEN":"Nuvalent, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvalent, Inc.(NUVL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nuvalent, Inc.(NUVL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nuvalent, Inc.,NUVL,Nuvalent, Inc.股票,Nuvalent, Inc.股票老虎,Nuvalent, Inc.股票老虎国际,Nuvalent, Inc.行情,Nuvalent, Inc.股票行情,Nuvalent, Inc.股价,Nuvalent, Inc.股市,Nuvalent, Inc.股票价格,Nuvalent, Inc.股票交易,Nuvalent, Inc.股票购买,Nuvalent, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvalent, Inc.(NUVL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nuvalent, Inc.(NUVL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}